These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 24927058)
1. Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease. Alisi A; Nobili V; Ceccarelli S; Panera N; De Stefanis C; De Vito R; Vitali R; Bedogni G; Balsano C; Cucchiara S; Stronati L Expert Rev Mol Diagn; 2014 Jul; 14(6):763-71. PubMed ID: 24927058 [TBL] [Abstract][Full Text] [Related]
2. Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology. Yilmaz Y; Eren F Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):43-46. PubMed ID: 30134384 [TBL] [Abstract][Full Text] [Related]
3. Serum β-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis. Cengiz M; Ozenirler S; Kocabiyik M Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):57-63. PubMed ID: 26513612 [TBL] [Abstract][Full Text] [Related]
4. Serum Bile Acid Levels in Children With Nonalcoholic Fatty Liver Disease. Jahnel J; Zöhrer E; Alisi A; Ferrari F; Ceccarelli S; De Vito R; Scharnagl H; Stojakovic T; Fauler G; Trauner M; Nobili V J Pediatr Gastroenterol Nutr; 2015 Jul; 61(1):85-90. PubMed ID: 25729888 [TBL] [Abstract][Full Text] [Related]
5. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease. Mandelia C; Collyer E; Mansoor S; Lopez R; Lappe S; Nobili V; Alkhouri N J Pediatr Gastroenterol Nutr; 2016 Aug; 63(2):181-7. PubMed ID: 26835904 [TBL] [Abstract][Full Text] [Related]
6. Procoagulant imbalance in patients with non-alcoholic fatty liver disease. Tripodi A; Fracanzani AL; Primignani M; Chantarangkul V; Clerici M; Mannucci PM; Peyvandi F; Bertelli C; Valenti L; Fargion S J Hepatol; 2014 Jul; 61(1):148-54. PubMed ID: 24657400 [TBL] [Abstract][Full Text] [Related]
7. High sensitive CRP and pentraxine 3 as noninvasive biomarkers of nonalcoholic fatty liver disease. Maleki I; Rastgar A; Hosseini V; Taghvaei T; Rafiei A; Barzin M; Torabizadeh Z; Naghshvar F; Khalilian A Eur Rev Med Pharmacol Sci; 2014 Jun; 18(11):1583-90. PubMed ID: 24943967 [TBL] [Abstract][Full Text] [Related]
8. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. McPherson S; Stewart SF; Henderson E; Burt AD; Day CP Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772 [TBL] [Abstract][Full Text] [Related]
9. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. Kaswala DH; Lai M; Afdhal NH Dig Dis Sci; 2016 May; 61(5):1356-64. PubMed ID: 27017224 [TBL] [Abstract][Full Text] [Related]
10. Portal inflammation is independently associated with fibrosis and metabolic syndrome in pediatric nonalcoholic fatty liver disease. Mann JP; De Vito R; Mosca A; Alisi A; Armstrong MJ; Raponi M; Baumann U; Nobili V Hepatology; 2016 Mar; 63(3):745-53. PubMed ID: 26638195 [TBL] [Abstract][Full Text] [Related]
11. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Verma S; Jensen D; Hart J; Mohanty SR Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360 [TBL] [Abstract][Full Text] [Related]
12. Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects. Sato M; Kamada Y; Takeda Y; Kida S; Ohara Y; Fujii H; Akita M; Mizutani K; Yoshida Y; Yamada M; Hougaku H; Takehara T; Miyoshi E Liver Int; 2015 Mar; 35(3):925-35. PubMed ID: 25627311 [TBL] [Abstract][Full Text] [Related]
13. Serum high mobility group box 1 protein levels are not associated with either histological severity or treatment response in children and adults with nonalcoholic fatty liver disease. Yates KP; Deppe R; Comerford M; Masuoka H; Cummings OW; Tonascia J; Chalasani N; Vuppalanchi R; PLoS One; 2017; 12(11):e0185813. PubMed ID: 29095942 [TBL] [Abstract][Full Text] [Related]
15. Visfatin and TGF-Β1 in primary biliary cirrhosis and two other common liver diseases. Waluga M; Kukla M; Żorniak M; Kochel-Jankowska A; Kajor M; Krzemiński T; Kotulski R Folia Med Cracov; 2015; 55(4):59-70. PubMed ID: 26867120 [TBL] [Abstract][Full Text] [Related]
16. Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease. Patel V; Sanyal AJ; Sterling R Clin Liver Dis; 2016 May; 20(2):277-92. PubMed ID: 27063269 [TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor-I and -II levels are associated with the progression of nonalcoholic fatty liver disease in obese children. Cianfarani S; Inzaghi E; Alisi A; Germani D; Puglianiello A; Nobili V J Pediatr; 2014 Jul; 165(1):92-8. PubMed ID: 24607243 [TBL] [Abstract][Full Text] [Related]
18. Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease. Lebensztejn DM; Wierzbicka A; Socha P; Pronicki M; Skiba E; Werpachowska I; Kaczmarski M Acta Biochim Pol; 2011; 58(4):563-6. PubMed ID: 22140659 [TBL] [Abstract][Full Text] [Related]
19. Hematocrit is associated with fibrosis in patients with nonalcoholic steatohepatitis. Li Y; Liu L; Wang B; Wang J; Chen D Eur J Gastroenterol Hepatol; 2014 Mar; 26(3):332-8. PubMed ID: 24172912 [TBL] [Abstract][Full Text] [Related]
20. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation. Kim H; Lee K; Lee KW; Yi NJ; Lee HW; Hong G; Choi Y; You T; Suh SW; Jang JJ; Suh KS Clin Transplant; 2014 May; 28(5):521-9. PubMed ID: 24579874 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]